Assessment of the Efficacy of Stromal Vascular Fraction Treatment for Knee Osteoarthritis

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 20, 2018

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions
Knee Osteoarthritis
Interventions
BIOLOGICAL

SVF treatment

SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.

Trial Locations (1)

AD700

CelularClinic, Les Escaldes

All Listed Sponsors
lead

University of Andorra

OTHER

NCT04749758 - Assessment of the Efficacy of Stromal Vascular Fraction Treatment for Knee Osteoarthritis | Biotech Hunter | Biotech Hunter